185 related articles for article (PubMed ID: 36007246)
1. Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios.
Verano AL; You I; Donovan KA; Mageed N; Yue H; Nowak RP; Fischer ES; Wang ES; Gray NS
ACS Chem Biol; 2022 Sep; 17(9):2404-2410. PubMed ID: 36007246
[TBL] [Abstract][Full Text] [Related]
2. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
3. Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
[TBL] [Abstract][Full Text] [Related]
4. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
[TBL] [Abstract][Full Text] [Related]
5. Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.
Anderson NA; Cryan J; Ahmed A; Dai H; McGonagle GA; Rozier C; Benowitz AB
Bioorg Med Chem Lett; 2020 May; 30(9):127106. PubMed ID: 32184044
[TBL] [Abstract][Full Text] [Related]
6. [Cereblon as a primary target of IMiDs].
Ito T; Handa H
Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
[TBL] [Abstract][Full Text] [Related]
7. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
[TBL] [Abstract][Full Text] [Related]
8. A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues.
Yamanaka S; Horiuchi Y; Matsuoka S; Kido K; Nishino K; Maeno M; Shibata N; Kosako H; Sawasaki T
Nat Commun; 2022 Jan; 13(1):183. PubMed ID: 35013300
[TBL] [Abstract][Full Text] [Related]
9. Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders.
Steinebach C; Ng YLD; Sosič I; Lee CS; Chen S; Lindner S; Vu LP; Bricelj A; Haschemi R; Monschke M; Steinwarz E; Wagner KG; Bendas G; Luo J; Gütschow M; Krönke J
Chem Sci; 2020 Apr; 11(13):3474-3486. PubMed ID: 33133483
[TBL] [Abstract][Full Text] [Related]
10. Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras.
Chen H; Liu J; Kaniskan HÜ; Wei W; Jin J
J Med Chem; 2021 Aug; 64(16):12273-12285. PubMed ID: 34378936
[TBL] [Abstract][Full Text] [Related]
11. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
[TBL] [Abstract][Full Text] [Related]
12. Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs.
Min J; Mayasundari A; Keramatnia F; Jonchere B; Yang SW; Jarusiewicz J; Actis M; Das S; Young B; Slavish J; Yang L; Li Y; Fu X; Garrett SH; Yun MK; Li Z; Nithianantham S; Chai S; Chen T; Shelat A; Lee RE; Nishiguchi G; White SW; Roussel MF; Potts PR; Fischer M; Rankovic Z
Angew Chem Int Ed Engl; 2021 Dec; 60(51):26663-26670. PubMed ID: 34614283
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy.
Costacurta M; He J; Thompson PE; Shortt J
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834536
[TBL] [Abstract][Full Text] [Related]
14. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
[TBL] [Abstract][Full Text] [Related]
15. [Development of novel cereblon modulators and their target molecules].
Ito T
Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
[TBL] [Abstract][Full Text] [Related]
16. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
Ito T; Handa H
Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676
[TBL] [Abstract][Full Text] [Related]
17. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases.
Zhou L; Xu G
J Mol Biol; 2022 Mar; 434(5):167457. PubMed ID: 35045330
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of thalidomide and its derivatives.
Ito T; Handa H
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
[TBL] [Abstract][Full Text] [Related]
20. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment.
Dann GP; Liu H; Nowak RP; Jones LH
Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
